^
Association details:
| Biomarker: | EGFR L858R |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
Excerpt:
the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Source:
Title:
MEchanisms of resitance in EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtib Mécanismes de résistance chez des patients avec un cancer du poumon avancé non prétraité, EGFR muté, recevant un traitement par OSIMERTINIB
Excerpt:
...• The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19 deletions, L858R), either alone or in combination with other EGFR mutations. ...
Trial ID:
Source:
Title:
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Excerpt:
...- The tumor harbors an Ex19del or Ex21-L858R substitution (based on tumor tissue or plasma [ctDNA] assessment)....
Trial ID:
More C2 evidence
Source:
Title:
PET/CT imaging detect EGFR protein mutations of lung cancer with specific molecular probe 11C-AZD9291
Excerpt:
...EGFR mutation status was confirmed by ARMS fluorescence PCR, including 4 cases of 19del mutant, 4 cases of 21L858R mutant, and 2 cases of wild type; 3. ...
Trial ID:
Source:
Title:
A multicenter, open-label, single arm pilot study: Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS)
Excerpt:
...Tested and confirmed to be EGFR mutation-positive (including exon 19 deletion and exon 21 L858R); 6. ...
Trial ID:
Source:
Title:
Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma
Excerpt:
...The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion....
Trial ID:
Source:
Title:
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
Excerpt:
...The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19 deletions, L858R), either alone or in combination with other EGFR mutations....
Trial ID:
Source:
Title:
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Excerpt:
...The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R)....
Source:
Title:
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
Excerpt:
...Patients with EGFR sensitizing mutations (Ex19del or L858R)....
Trial ID:
Source:
Title:
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Excerpt:
...The resected lung adenocarcinoma should have actionable EGFR mutation, which is limited to L858R or exon 19 deletion....
Trial ID:
Less C2 evidence
Source:
Title:
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS)
Published date:
05/19/2021
Excerpt:
Half (9/18) of the patients had EGFR exon 21 L858R mutations and the other half (9/18) had EGFR exon 19del mutations. Amongst all 15 patients who completed efficacy assessment after neoadjuvant osimertinib, the response rate (RR) was 73.3% (11/15) and the disease control rate (DCR) was 100% (15/15)....Interim analysis from this study indicated neoadjuvant osimertinib as an effective and feasible treatment in patients with resectable stage II-IIIB EGFRm NSCLC.
DOI:
10.1200/JCO.2021.39.15_suppl.8524
Source:
Title:
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Excerpt:
Biopsy of a liver lesion demonstrated adenocarcinoma positive for TTF-1 and Napsin-A by immunohistochemistry. An EGFRL858R mutation was detected in the tumor with targeted NGS using the Illumina MiSeqDx platform...she was started on 80 mg osimertinib QD. She had an excellent response, with shrinkage of all sites of disease and resolution of brain metastases.Imaging performed every ~2 months showed a continued response, until 8.5 months after initiation of osimertinib when the patient was found to have growth of a liver lesion.
DOI:
10.1158/0008-5472.CAN-19-3819
Test:
Source:
Title:
In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs
Published date:
11/10/2017
Excerpt:
Here, we present an in vivo imaging model for brain tumors using human cancer cell lines, including the EGFR-L858R/T790M-positive H1975 lung adenocarcinoma cells...KM12SM colorectal cancer cells containing the TPM3-NTRK1 gene fusion. Human lung adenocarcinoma H1975 cells, harboring an EGFR‐L858R‐sensitive mutation or an EGFR‐T790M‐resistant mutation, were resistant to the first‐generation EGFR‐TKI gefitinib, but were sensitive to the third‐generation EGFR‐TKI osimertinib.
DOI:
10.1002/cam4.1255
